Table 1 Baseline patient and disease characteristics (intent-to-treat population)
Characteristic | R-CHOP (N = 710) | G-CHOP (N = 704) |
|---|---|---|
Median age (range), years | 62.0 (18–83) | 62.0 (18–86) |
Male sex, n (%) | 382 (53.8) | 368 (52.3) |
Geographic region, n (%) | ||
Eastern Europe | 99 (13.9) | 97 (13.8) |
Western Europe | 215 (30.3) | 211 (30.0) |
Central and South America | 19 (2.7) | 13 (1.8) |
North America | 107 (15.1) | 109 (15.5) |
Asia | 256 (36.1) | 258 (36.6) |
Other | 14 (2.0) | 16 (2.3) |
ECOG PS, n (%)a | ||
0–1 | 611 (86.1) | 617 (87.8) |
2 | 99 (13.9) | 86 (12.2) |
Ann Arbor stage, n (%)b | ||
I and II | 171 (24.1) | 169 (24.0) |
III and IV | 538 (75.9) | 535 (76.0) |
IPI risk group, n (%) | ||
Low/low-intermediate | 408 (57.5) | 374 (53.1) |
High-intermediate | 192 (27.0) | 220 (31.3) |
High | 110 (15.5) | 110 (15.6) |
No. of planned CHOP cycles, n (%) | ||
6 | 524 (73.8) | 521 (74.0) |
8 | 186 (26.2) | 183 (26.0) |
LDH elevated, n(%)c | ||
Yes | 403 (57.1) | 415 (59.0) |
Extranodal involvement, n (%) | ||
Yes | 466 (65.6) | 484 (68.8) |
Bulky disease (≥ 7.5 cm), n (%)d | 262 (37.0) | 261 (37.2) |
Median time from diagnosis to randomization (range), dayse | 25.0 (1.0–264.8) | 23.1 (3.0–1104.9) |
Cell of origin, n (%)f | ||
GCB | 269 (58.2) | 271 (57.5) |
ABC | 118 (25.5) | 125 (26.5) |
Unclassified | 75 (16.2) | 75 (15.9) |